Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03799783
Other study ID # 4422/AO/18
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date March 1, 2018
Est. completion date September 28, 2019

Study information

Verified date January 2021
Source Azienda Ospedaliera di Padova
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Children's compliance during diagnostic or therapeutic procedures is a challenge, often requiring the use of sedative and/or analgesic drugs. Electroencephalogram (EEG) needs stillness for a medium-long period but, at the same time, the use of any drug for sedation may affect the exam through an interference with EEG waves. Dexmedetomidine is a selective ∝2-adrenergic agonist with sedative and anxiolytic properties, with a long effect and which does not alter EEG pattern. The aim of this interventional study is to evaluate the effectiveness, safety and feasibility of dexmedetomidine for sedation during EEG in children who are not cooperative. Children affected by behavioral disorders and requiring sedation to perform EEG were considered. The protocol establishes to administer IV dexmedetomidine (loading dose and continued infusion) to reach a targeted level of sedation (Pediatric Sedation State Scale = 2). Vital signs (SatO2, RR, EtCO2, HR, BP) and level of sedation are recorded before, during and after procedure until the offset.


Description:

Compliance during diagnostic or therapeutic procedures is a very frequent challenge in children. Procedural sedation and analgesia represents an effective answer to this problem. Electroencephalogram (EEG) is a procedure which needs stillness for a medium-long period. Whereas the majority of children carry out this procedure without sedation, patients with behavioral problems, who frequently need to rule out the presence of seizures as associated symptoms or different disease, often show an insufficient compliance. Sedative drugs usually interfere with EEG cerebral waves pattern, so they can not be used. Dexmedetomidine is a selective ∝2-adrenergic agonist with prevalent sedative and anxiolytic properties, with a long effect and which does not alter EEG pattern. The aim of this interventional study is to evaluate effectiveness, safety and feasibility of dexmedetomidine for sedation during EEG in children who are not cooperative. Children referred to the Pediatric Neurology Department of the Pediatric Hospital of Padova and required sedation to perform EEG were considered in the study. The protocol establishes to administer dexmedetomidine IV 2 μg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 μg/kg/h until procedure was complete. The loading dose can be repeated up to two times, if needed, to achieve the targeted level of Pediatric Sedation State Scale (PSSS) of 2 (quiet, asleep or awake, not moving during procedure, and no frown or brow furrow indicating pain or anxiety, no verbalization of any complaint). Vital signs (SatO2, RR, EtCO2, HR, BP) and level of sedation are recorded before, during and after procedure until the complete awake of the patient. The quality of the EEG pattern was also evaluated. Occurrence and type of adverse events are registered during this period. Finally, the caregivers' opinion about the quality of the sedation and the presence of any sleep disturbance at home during the next 12 hours after the procedure were considered.


Recruitment information / eligibility

Status Completed
Enrollment 19
Est. completion date September 28, 2019
Est. primary completion date February 28, 2019
Accepts healthy volunteers No
Gender All
Age group 1 Month to 18 Years
Eligibility Inclusion Criteria: - children affected by behavior disorders who underwent EEG procedure with sedation - written informed consent Exclusion Criteria: - ASA > 2 - hypersensitivity of active substance - therapy with beta blockers or digoxin, arrhythmia

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
dexmedetomidine
To administer dexmedetomidine IV 2 µg/kg in 10 minutes (loading dose) followed by continuous infusion at a rate of 1 µg/kg/h until procedure was complete

Locations

Country Name City State
Italy Pediatric Intensive Care Unit - Department of Woman's and Child's Health - Azienda Ospedaliera di Padova Padova PD

Sponsors (1)

Lead Sponsor Collaborator
Azienda Ospedaliera di Padova

Country where clinical trial is conducted

Italy, 

References & Publications (8)

Coté CJ, Wilson S; AMERICAN ACADEMY OF PEDIATRICS; AMERICAN ACADEMY OF PEDIATRIC DENTISTRY. Guidelines for Monitoring and Management of Pediatric Patients Before, During, and After Sedation for Diagnostic and Therapeutic Procedures: Update 2016. Pediatric — View Citation

Cravero JP, Askins N, Sriswasdi P, Tsze DS, Zurakowski D, Sinnott S. Validation of the Pediatric Sedation State Scale. Pediatrics. 2017 May;139(5). pii: e20162897. doi: 10.1542/peds.2016-2897. — View Citation

Keidan I, Ben-Menachem E, Tzadok M, Ben-Zeev B, Berkenstadt H. Electroencephalography for children with autistic spectrum disorder: a sedation protocol. Paediatr Anaesth. 2015 Feb;25(2):200-5. doi: 10.1111/pan.12510. Epub 2014 Aug 22. — View Citation

Lubisch N, Roskos R, Berkenbosch JW. Dexmedetomidine for procedural sedation in children with autism and other behavior disorders. Pediatr Neurol. 2009 Aug;41(2):88-94. doi: 10.1016/j.pediatrneurol.2009.02.006. — View Citation

Mason KP, O'Mahony E, Zurakowski D, Libenson MH. Effects of dexmedetomidine sedation on the EEG in children. Paediatr Anaesth. 2009 Dec;19(12):1175-83. doi: 10.1111/j.1460-9592.2009.03160.x. — View Citation

National Clinical Guideline Centre (UK). Sedation in Children and Young People: Sedation for Diagnostic and Therapeutic Procedures in Children and Young People [Internet]. London: Royal College of Physicians (UK); 2010 Dec. Available from http://www.ncbi. — View Citation

Sulton C, McCracken C, Simon HK, Hebbar K, Reynolds J, Cravero J, Mallory M, Kamat P. Pediatric Procedural Sedation Using Dexmedetomidine: A Report From the Pediatric Sedation Research Consortium. Hosp Pediatr. 2016 Sep;6(9):536-44. doi: 10.1542/hpeds.201 — View Citation

Zub D, Berkenbosch JW, Tobias JD. Preliminary experience with oral dexmedetomidine for procedural and anesthetic premedication. Paediatr Anaesth. 2005 Nov;15(11):932-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients That Reach a Score Equal or Lower Than 2 Ten Minutes After the Infusion of Dexmedetomidine (Assessed With the PSSS Pediatric Sedation State Scale) the PSSS is a validated scale for assessing the level of procedural sedation. It is a 6 items scale , from 0 to 5, where 5 is an alert patient and 0 is a deep sedation with abnormal vital signs. We evaluate patients 10 minutes after the infusion of dexmedetomidine. 10 minutes
Secondary Number of Patients With Adverse Events any adverse event potentially related with DEX-administration during and immediately after DEX infusion, up to 150 minutes after DEX infusion (time to first awakening)
See also
  Status Clinical Trial Phase
Recruiting NCT03692390 - Virtual Reality vs. Standard-of-Care for Comfort Before and After Sedation in the Emergency Department N/A
Completed NCT02145169 - Inhaled Nitrous Oxide for the Prevention of Emergence Reaction During Ketamine Administration in Adults, a Pilot Study N/A
Recruiting NCT05595798 - EEG Spectral Pattern of Deep Sedation-induced Airway Adverse Effects
Completed NCT01260662 - Randomized Clinical Trial of Propofol, 1:1 and 4:1 Combination of Propofol and Ketamine for Procedural Sedation Phase 4
Completed NCT00784498 - Procedural Sedation Using Propofol Versus Midazolam/Ketamine in the Adult Emergency Department Phase 4
Completed NCT00327392 - A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures. Phase 2/Phase 3
Recruiting NCT04873596 - Dexmedetomidine and Midazolam Nebulization as Sedation During Cesarean Delivery in Pre-eclampsia Phase 2
Completed NCT03329014 - A Trial of Intranasal Remimazolam Pharmacokinetics, Pharmacodynamics, Safety and Bioavailability Phase 1
Recruiting NCT06414395 - The Effects of Different Loading Doses of Dexmedetomidine on The Bispectral Index-Guided Propofol Sedation in Patients Undergoing Advanced Upper Gastrointestinal Endoscopic Procedures: A Randomized Control Study Phase 4
Recruiting NCT03860831 - Intranasal Ketamine and Midazolam Mixture for Procedural Sedation in Children With Mental Disabilities: Phase 1
Completed NCT00869440 - Dose-Finding Safety Study Evaluating Remimazolam (CNS 7056) in Patients Undergoing Diagnostic Upper GI Endoscopy Phase 2
Not yet recruiting NCT05757622 - Electroencephalogram Based Real-Time Sedation Level Prediction
Completed NCT02180737 - Dexmedetomidine for Sedation During Radiological Interventional Procedures Phase 4
Not yet recruiting NCT01227174 - Safety and Efficacy of Propofol Only Sedation in Oral and Maxillofacial Surgery Phase 4
Recruiting NCT03499886 - Low-Dose Intravenous Ketamine Bolus Versus Conventional Technique Phase 2/Phase 3
Completed NCT03747432 - Comparison of Procedural Sedation With Propofol and Dexmedetomidine During Transcatheter Aortic Valve Implantation Phase 4
Recruiting NCT06203522 - Factors Associated With Successful Completion of MRI in Children Undergoing a Vigil Sedation With Dexmedetomidin
Withdrawn NCT05783492 - INK Feasibility Study Phase 3
Recruiting NCT04686448 - Ketofol Versus Fenofol as Procedural Sedation for Carpal Tunnel Release Phase 1/Phase 2
Completed NCT02955732 - Pharmacological Characteristics of Intranasally Given Dexmedetomidine in Paediatric Patients Phase 4